Source:http://linkedlifedata.com/resource/pubmed/id/10199463
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1999-4-15
|
pubmed:abstractText |
This study evaluated tolerance, local control, and short-term survival in patients with locally advanced non-small-cell lung carcinoma treated with induction chemotherapy followed by radical hyperfractionated radiotherapy with concurrent chemotherapy. Thirty-one patients with stage IIIa (N2) or IIIb tumors were treated with cis-platinum-based induction chemotherapy for 1 to 4 courses followed by radical hyperfractionated radiotherapy (69.6 Gy) with concurrent chemotherapy given at the beginning and end of radiotherapy. Induction chemotherapy produced no complete responses and 18 (58%) partial responses. After completion of radiotherapy, 4 patients had complete response (13%) and 23 patients (74%) partial response. The patterns of failure were as follows: intrathoracic, 6 patients (22%); intrathoracic + distant metastasis, 6 patients (22%); distant metastasis without thoracic failure, 5 patients (19%). Six patients of the 12 with intrathoracic failure experienced in-field radiotherapy pure local failure. At the time of this analysis, 10 patients were alive and well (4 complete and 6 partial responders). Actuarial survival projected at 39 months is 35%. No benefit was observed for those patients responding to induction chemotherapy. Toxicity was as follows: grade III neutropenic fever in 4 patients (13%), grade IV neutropenia in 13 patients (42%), pneumonia in 6 patients (19%), grade III esophagitis in 4 patients (13%) and severe clinical pneumonitis in 1 patient (3%). Induction chemotherapy followed by chemoradiotherapy is feasible, and the preliminary results are encouraging. Complete response after radiotherapy appeared to be related to short-term disease-free survival, and decisions based on the response to chemotherapy may be equivocal.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0277-3732
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
22
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
203-8
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:10199463-Adult,
pubmed-meshheading:10199463-Aged,
pubmed-meshheading:10199463-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10199463-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:10199463-Cisplatin,
pubmed-meshheading:10199463-Combined Modality Therapy,
pubmed-meshheading:10199463-Female,
pubmed-meshheading:10199463-Humans,
pubmed-meshheading:10199463-Lung Neoplasms,
pubmed-meshheading:10199463-Male,
pubmed-meshheading:10199463-Middle Aged,
pubmed-meshheading:10199463-Neoplasm Staging,
pubmed-meshheading:10199463-Radiotherapy Dosage,
pubmed-meshheading:10199463-Survival Analysis,
pubmed-meshheading:10199463-Treatment Failure
|
pubmed:year |
1999
|
pubmed:articleTitle |
Induction platinum-based chemotherapy followed by radical hyperfractionated radiotherapy with concurrent chemotherapy in the treatment of locally advanced non-small-cell carcinoma of the lung.
|
pubmed:affiliation |
Department of Oncology Clínica Universitaria, Facultad de Medicina, Universidad de Navarra, Pamplona, Spain.
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|